Related references
Note: Only part of the references are listed.Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Emerging targeted therapies for bladder cancer: a disease waiting for a drug
Simon J. Dovedi et al.
CANCER AND METASTASIS REVIEWS (2009)
Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer
Jose J. Mansure et al.
CANCER BIOLOGY & THERAPY (2009)
Targeting Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
EFFECTS OF MTOR INHIBITOR EVEROLIMUS (RAD001) ON BLADDER CANCER CELLS
Edmund Chiong et al.
JOURNAL OF UROLOGY (2009)
QUANTIFICATION OF SUNITINIB'S ANTITUMOR EFFECTS IN A LOCALIZED ORTHOTOPIC BLADDER CANCER MODEL
Amit R. Patel et al.
JOURNAL OF UROLOGY (2009)
Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model
Guru Sonpavde et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2009)
Rapamycin Inhibits In Vitro Growth and Release of Angiogenetic Factors in Human Bladder Cancer
Guido Fechner et al.
UROLOGY (2009)
Molecular targets and targeted therapies in bladder cancer management
Ramy F. Youssef et al.
WORLD JOURNAL OF UROLOGY (2009)
Advanced bladder cancer: Status of first-line chemotherapy and the search for active agents in the second-line setting
David J. Gallagher et al.
CANCER (2008)
Final results of a phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC)
D. J. Gallagher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Hypoxia-inducible factor-1α expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma
C. -Y Chai et al.
JOURNAL OF CLINICAL PATHOLOGY (2008)
Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry
Ferenc Pinter et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2008)
Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies
Jorge A. Garcia et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-Deficient glioblastoma
Tim F. Cloughesy et al.
PLOS MEDICINE (2008)
Prognostic significance of HIF-1α polymorphisms in transitional cell carcinoma of the bladder
Junichi Nadaoka et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers
Rob J. Jones et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: Scientific rationale and study design
Deborah A. Bradley et al.
CLINICAL GENITOURINARY CANCER (2007)
Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase-mediated mTOR activation in tuberous sclerosis and human cancer
Li Ma et al.
CANCER RESEARCH (2007)
RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model
Seiji Mabuchi et al.
CLINICAL CANCER RESEARCH (2007)
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma:: Results of a multicenter phase II National Cancer Institute trial
Maha H. A. Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Immunohistochemical expression of hypoxia inducible factor-la and its downstream molecules in sarcomatoid renal cell carcinoma
Satish K. Tickoo et al.
JOURNAL OF UROLOGY (2007)
Hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha expression in bladder cancer and their associations with other angiogenesis-related proteins
E. Ioachim et al.
UROLOGIA INTERNATIONALIS (2006)
The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion
X Wu et al.
BJU INTERNATIONAL (2004)
Gemcitabine and cisplatin versus methotrexate vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large randomized, multinational, multicenter, phase III study
H von der Maase et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
